BR112022025918A2 - Compostos de oxazolidinona, composições lipossomais que compreendem compostos de oxazolidinona e métodos de uso dos mesmos - Google Patents
Compostos de oxazolidinona, composições lipossomais que compreendem compostos de oxazolidinona e métodos de uso dos mesmosInfo
- Publication number
- BR112022025918A2 BR112022025918A2 BR112022025918A BR112022025918A BR112022025918A2 BR 112022025918 A2 BR112022025918 A2 BR 112022025918A2 BR 112022025918 A BR112022025918 A BR 112022025918A BR 112022025918 A BR112022025918 A BR 112022025918A BR 112022025918 A2 BR112022025918 A2 BR 112022025918A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- oxazolidinone compounds
- methods
- oxazolidinone
- allow
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSTOS DE OXAZOLIDINONA, COMPOSIÇÕES LIPOSSOMAIS QUE COMPREENDEM COMPOSTOS DE OXAZOLIDINONA E MÉTODOS DE USO DOS MESMOS. São divulgados composições e métodos para o tratamento de tuberculose, bem como outras infecções por micobactérias e bactérias gram-positivas. Estas composições contêm uma oxazolidinona altamente potente e seletiva encapsulada com alta eficiência para maximizar o potencial de dosagem de fármacos de baixa toxicidade e são estáveis na presença de plasma. As composições têm circulação longa e mantêm seu fármaco encapsulado enquanto estão na circulação após a dosagem intravenosa para permitir o acúmulo eficiente no local da infecção bacteriana ou micobacteriana. As doses altas que podem ser atingidas quando combinadas com propriedades de circulação longa e a retenção altamente estável do fármaco permitem uma frequência reduzida de administração quando comparadas com administrações diárias ou duas vezes ao dia de outros fármacos tipicamente utilizados para tratar estas infecções.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063040810P | 2020-06-18 | 2020-06-18 | |
US17/351,631 US11555033B2 (en) | 2020-06-18 | 2021-06-18 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof |
PCT/US2021/038131 WO2021258013A1 (en) | 2020-06-18 | 2021-06-18 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022025918A2 true BR112022025918A2 (pt) | 2023-03-14 |
Family
ID=79025353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022025918A BR112022025918A2 (pt) | 2020-06-18 | 2021-06-18 | Compostos de oxazolidinona, composições lipossomais que compreendem compostos de oxazolidinona e métodos de uso dos mesmos |
Country Status (9)
Country | Link |
---|---|
US (5) | US20230219941A1 (pt) |
JP (1) | JP2023531666A (pt) |
KR (1) | KR20230052873A (pt) |
AU (1) | AU2021292747A1 (pt) |
BR (1) | BR112022025918A2 (pt) |
CA (1) | CA3183397A1 (pt) |
IL (1) | IL299155A (pt) |
MX (1) | MX2022016063A (pt) |
WO (1) | WO2021258013A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230052873A (ko) * | 2020-06-18 | 2023-04-20 | 아카제라 메디신즈, 인크. | 옥사졸리디논 화합물, 옥사졸리디논 화합물을 포함하는 리포좀 조성물 및 이의 사용 방법 |
EP4296674A1 (en) | 2022-06-20 | 2023-12-27 | Université Toulouse III - Paul Sabatier | Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis |
GB202210829D0 (en) * | 2022-07-25 | 2022-09-07 | Micropore Tech Ltd | Continuous process |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH085107B2 (ja) | 1988-08-04 | 1996-01-24 | ファナック株式会社 | 電動式射出成形機における位置決め方式 |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
JPH07508985A (ja) | 1992-07-08 | 1995-10-05 | ジ・アップジョン・カンパニー | マイコバクテリウム・チュバーキュローシスに対して有効な5’−インドリニルオキサゾリジノン類 |
JPH0873455A (ja) | 1994-03-15 | 1996-03-19 | Upjohn Co:The | オキサゾリジノン誘導体及びこれを有効成分とする医薬組成物 |
US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
US6110491A (en) | 1996-10-22 | 2000-08-29 | Hermes Biosciences, Inc. | Compound-loaded liposomes and methods for their preparation |
CN1433413A (zh) * | 2000-06-05 | 2003-07-30 | 东亚制药株式会社 | 新的噁唑烷酮衍生物及其制备方法 |
CZ2003228A3 (cs) | 2000-07-17 | 2003-06-18 | Ranbaxy Laboratories Limited | Oxazolidinonové deriváty jako antimikrobiální látky |
WO2003008389A1 (en) | 2001-07-16 | 2003-01-30 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as potential antimicrobials |
DE60237162D1 (de) | 2001-10-03 | 2010-09-09 | Celator Pharmaceuticals Inc | Liposomenladung mit metallionen |
WO2003075890A1 (en) | 2002-03-05 | 2003-09-18 | Transave, Inc. | Methods for entrapment of bioactive agent in a liposome or lipid complex |
KR20040106551A (ko) | 2002-05-15 | 2004-12-17 | 랜박시 래보러터리스 리미티드 | 페닐 옥사졸리디논 유도체의 다형 제제 |
BR0215921A (pt) | 2002-07-29 | 2005-09-13 | Ranbaxy Lab Ltd | Derivados de oxazolidinona utilizáveis como antimicrobianos e processo de sua preparação |
WO2004048350A2 (en) | 2002-11-28 | 2004-06-10 | Astrazeneca Ab | Oxazolidinones as antibacterial agents |
GB0229518D0 (en) | 2002-12-19 | 2003-01-22 | Astrazeneca Ab | Chemical compounds |
WO2004099199A1 (en) | 2003-05-06 | 2004-11-18 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
US8324398B2 (en) | 2003-06-03 | 2012-12-04 | Rib-X Pharmaceuticals, Inc. | Process for the synthesis of biaryl oxazolidinones |
KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
WO2005082899A1 (en) | 2004-01-28 | 2005-09-09 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
WO2005107712A1 (en) | 2004-05-03 | 2005-11-17 | Hermes Biosciences, Inc. | Liposomes useful for drug delivery |
AU2005247668A1 (en) | 2004-05-25 | 2005-12-08 | Astrazeneca Ab | 3- `4- {6-substituted alkanoyl) pyridin-3-yl} -3-phenyl! -5- (1H-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents |
CA2567929A1 (en) | 2004-05-25 | 2005-12-08 | Astrazeneca Ab | 3- {4- (pyridin-3-yl) phenyl} -5- (1h-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents |
WO2006035283A1 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
CN101072588B (zh) | 2004-10-06 | 2012-11-28 | 不列颠哥伦比亚抗癌机构 | 用于治疗癌症的具有改善的药物保留的脂质体 |
WO2006051408A1 (en) | 2004-11-11 | 2006-05-18 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
EP1745784A1 (en) | 2005-06-27 | 2007-01-24 | Ferrer Internacional, S.A. | Oxazolidinone derivatives and use thereof as antibiotics |
EP3718532A1 (en) * | 2005-12-08 | 2020-10-07 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
KR101023174B1 (ko) | 2008-09-24 | 2011-03-18 | 주식회사 레고켐 바이오사이언스 | 사이클릭 아미독심 또는 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물 |
SG10201702946RA (en) | 2008-10-10 | 2017-05-30 | Merck Sharp & Dohme | Methods for preparing oxazolidinones and compositions containing them |
CN102439006A (zh) | 2009-02-03 | 2012-05-02 | 特留斯治疗学公司 | (r)-3-(4-(2-(2-甲基四唑-5-基)吡啶-5-基)-3-氟苯基)-5-羟甲基噁唑烷-2-酮二氢磷酸酯的晶型 |
US8580767B2 (en) | 2009-05-28 | 2013-11-12 | Trius Therapeutics, Inc. | Oxazolidinone containing dimer compounds, compositions and methods to make and use |
US20120065170A1 (en) | 2010-09-10 | 2012-03-15 | Micurx Pharmaceuticals, Inc. | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections |
US9359344B2 (en) | 2011-09-29 | 2016-06-07 | Xuanzhu Pharma Co., Ltd. | Biaryl heterocycle substituted oxazolidinone antibacterial agents |
WO2016009401A2 (en) | 2014-07-18 | 2016-01-21 | Dr. Reddy's Laboratories Limited | Preparation of tedizolid phosphate |
CN106928214A (zh) | 2014-09-17 | 2017-07-07 | 博瑞生物医药(苏州)股份有限公司 | 一种噁唑烷酮类化合物及其中间体的制备方法 |
WO2016041505A1 (zh) | 2014-09-17 | 2016-03-24 | 正大天晴药业集团股份有限公司 | 一种磷酸特地唑胺、其中间体以及它们的制备方法 |
CN104327119A (zh) | 2014-10-17 | 2015-02-04 | 苏州明锐医药科技有限公司 | 磷酸泰地唑胺的制备方法 |
WO2016088101A1 (en) | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Processes for the preparation of tedizolid phosphate and its intermediates |
WO2016088102A1 (en) | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Processes for the preparation of tedizolid phosphate and its intermediates |
WO2016088100A1 (en) | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Processes for the preparation of tedizolid phosphate and its intermediates |
WO2016088103A1 (en) | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | A process for the preparation of tedizolid phosphate |
WO2017066964A1 (en) | 2015-10-22 | 2017-04-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
CN106632298B (zh) | 2015-11-03 | 2021-06-01 | 上海科胜药物研发有限公司 | 一种泰地唑胺的制备方法及其中间体 |
KR101855334B1 (ko) | 2015-12-11 | 2018-06-08 | 에스티팜 주식회사 | 옥사졸리디논 유도체의 중간체 제조방법 |
US20180369143A1 (en) | 2015-12-15 | 2018-12-27 | British Columbia Cancer Agency Branch | Metal complexed therapeutic agents and lipid-based nanoparticulate formulations thereof |
WO2017143112A2 (en) | 2016-02-17 | 2017-08-24 | The Johns Hopkins University | An oxazolidinone for treatment of infections with mycobacterium tuberculosis |
WO2018170664A1 (en) | 2017-03-20 | 2018-09-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
KR20210038632A (ko) | 2018-07-25 | 2021-04-07 | 카딜라 핼쓰캐어 리미티드 | 포유류 감염 치료를 위한 신규 화합물 |
US20220081403A1 (en) | 2019-01-18 | 2022-03-17 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
WO2021184339A1 (en) | 2020-03-20 | 2021-09-23 | Merck Sharp & Dohme Corp. | Oxazolidinone compound and methods of use thereof as an antibacterial agent |
KR20230052873A (ko) * | 2020-06-18 | 2023-04-20 | 아카제라 메디신즈, 인크. | 옥사졸리디논 화합물, 옥사졸리디논 화합물을 포함하는 리포좀 조성물 및 이의 사용 방법 |
-
2021
- 2021-06-18 KR KR1020237001446A patent/KR20230052873A/ko unknown
- 2021-06-18 AU AU2021292747A patent/AU2021292747A1/en active Pending
- 2021-06-18 JP JP2022578853A patent/JP2023531666A/ja active Pending
- 2021-06-18 CA CA3183397A patent/CA3183397A1/en active Pending
- 2021-06-18 US US18/002,115 patent/US20230219941A1/en active Pending
- 2021-06-18 IL IL299155A patent/IL299155A/en unknown
- 2021-06-18 MX MX2022016063A patent/MX2022016063A/es unknown
- 2021-06-18 US US17/351,631 patent/US11555033B2/en active Active
- 2021-06-18 BR BR112022025918A patent/BR112022025918A2/pt unknown
- 2021-06-18 WO PCT/US2021/038131 patent/WO2021258013A1/en unknown
-
2022
- 2022-05-06 US US17/738,216 patent/US11566023B2/en active Active
- 2022-12-01 US US18/060,900 patent/US20230126415A1/en active Pending
- 2022-12-13 US US18/065,370 patent/US20230348447A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230219941A1 (en) | 2023-07-13 |
IL299155A (en) | 2023-02-01 |
MX2022016063A (es) | 2023-04-11 |
KR20230052873A (ko) | 2023-04-20 |
US20230348447A1 (en) | 2023-11-02 |
AU2021292747A1 (en) | 2023-02-23 |
US20220274975A1 (en) | 2022-09-01 |
US11566023B2 (en) | 2023-01-31 |
CA3183397A1 (en) | 2021-12-23 |
JP2023531666A (ja) | 2023-07-25 |
WO2021258013A1 (en) | 2021-12-23 |
US20230126415A1 (en) | 2023-04-27 |
US11555033B2 (en) | 2023-01-17 |
US20210403463A1 (en) | 2021-12-30 |
AU2021292747A2 (en) | 2023-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022025918A2 (pt) | Compostos de oxazolidinona, composições lipossomais que compreendem compostos de oxazolidinona e métodos de uso dos mesmos | |
BR112023024646A2 (pt) | Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina | |
BRPI0513673A (pt) | método para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, veìculo utilizado na administração enteral de compostos biologicamente ativos, composição farmacêutica e uso de uma quantidade eficaz de um ou mais derivados de fosfato | |
BR0111126A (pt) | Derivados de aminoácidos cìclicos úteis como agentes farmacêuticos | |
AR025959A1 (es) | DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
NO964433D0 (no) | Farmasöytiske preparater på basis av derivater av taxanklassen | |
BR112022013009A2 (pt) | Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina | |
BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
SE0950390L (sv) | System och process för tillverkning av en lösning med suspenderade fasta ämnen och användningar därför | |
RU2655808C2 (ru) | Фармацевтическая комбинированная композиция для местного и наружного применения на основе бактериолитического и протеолитического комплекса ферментов | |
UY26678A1 (es) | El uso de composiciones a base de antibióticos de azalidos para tratar o prevenir una infección bacteriana o protozoaria en mamíferos | |
AR108562A1 (es) | Método para la preparación del conjugado hialuronidasa con derivados de piperazina de polietileno y la aplicación del conjugado obtenido | |
Farber | Clinical and biological studies with actinomycins | |
Ujjani et al. | Bendamustine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma | |
Çökmez et al. | Effect of transdermal glyceryl trinitrate and anti‐inflammatory gel in infusion phlebitis | |
DE50113974D1 (de) | Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen | |
Patel et al. | Randomized controlled trial comparing hyaluronic acid, platelet-rich plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee-Letter to the Editor & Author Response | |
AR045070A1 (es) | Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico | |
RU2348400C1 (ru) | Фармацевтический препарат для местного и наружного применения на основе низкомолекулярного индуктора интерферона | |
BR112022005723A2 (pt) | Compostos de indol carboxamida e seu uso para o tratamento de infecções micobacterianas | |
BRPI0412506A (pt) | células autólogas que induzem à autotoleráncia de origem monocìtica e seu uso em preparações farmacêuticos | |
Ali et al. | Dössekker's atypical tuberous myxoedema, a rare variant of scleromyxoedema | |
BR112023023715A2 (pt) | Pluralidade de partículas compreendendo tasquinimod, composição farmacêutica, unidade de dosagem farmacêutica, uso da pluralidade de partículas ou da composição farmacêutica, e, método para o tratamento do câncer | |
Geeta et al. | In silico evaluation of the efficacies of two different medicaments against Enterococcus faecalis | |
Frenk et al. | Actuality of amizon administration to the ointment with poplar extract |